An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007115/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple
Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and
who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age
(ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma
(RRMM).
提供机构：
Vivli
创建时间：
2021-05-06
